Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06603571 | A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes | PHASE2 | ACTIVE NOT_RECRUITING | 350 | — | — | Sep 20, 2024 | Aug 1, 2026 | Sep 26, 2025 | 52 | United States, Argentina |
| NCT06230523 | A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight | PHASE2 | COMPLETED | 263 | — | — | Feb 5, 2024 | Aug 14, 2025 | Aug 28, 2025 | 46 | United States, Argentina |
| NCT06297616 | A Study of LY3841136 in Japanese Participants With Obesity or Overweight | PHASE1 | COMPLETED | 128 | — | — | Apr 15, 2024 | Nov 21, 2025 | Jan 16, 2026 | 3 | Japan |
| NCT05295940 | A Study of LY3841136 in Healthy and Overweight Participants | PHASE1 | COMPLETED | 148 | — | — | Mar 30, 2022 | Jan 25, 2024 | Apr 1, 2024 | 3 | United States |
A summary of treatment emergent adverse events (TEAEs), SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
A summary of treatment emergent adverse events (TEAEs), SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3841136 Dose 1 | EXPERIMENTAL | Participants will receive LY3841136 subcutaneously (SC) |
| LY3841136 Dose 2 | EXPERIMENTAL | Participants will receive LY3841136 SC |
| LY3841136 Dose 3 | EXPERIMENTAL | Participants will receive LY3841136 SC |
| LY3841136 Dose 1 + Tirzepatide Dose 1 | EXPERIMENTAL | Participants will receive LY3841136 SC and Tirzepatide SC |
| LY3841136 Dose 2 + Tirzepatide Dose 1 | EXPERIMENTAL | Participants will receive LY3841136 SC and Tirzepatide SC |
| LY3841136 Dose 2 + Tirzepatide Dose 2 | EXPERIMENTAL | Participants will receive LY3841136 SC and Tirzepatide SC |
| LY3841136 Dose 3 + Tirzepatide Dose 3 | EXPERIMENTAL | Participants will receive LY3841136 SC and Tirzepatide SC |
| Tirzepatide Dose 3 | ACTIVE_COMPARATOR | Participants will receive Tirzepatide SC |
| LY3841136 Dose 2 + Tirzepatide Dose 3 | EXPERIMENTAL | Participants will receive LY3841136 SC and Tirzepatide SC |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo administered SC. |
| LY3841136 Dose 4 | EXPERIMENTAL | Participants will receive LY3841136 SC. |
| LY3841136 Dose 5 | EXPERIMENTAL | Participants will receive LY3841136 SC |
| LY3841136 Dose 6 | EXPERIMENTAL | Participants will receive LY3841136 SC |
| Part A: LY3841136 | EXPERIMENTAL | LY3841136 administered subcutaneously (SC) |
| Part A: Placebo | PLACEBO_COMPARATOR | Placebo administered SC |
| Part B: Tirzepatide + LY3841136-Placebo | EXPERIMENTAL | Tirzepatide administered SC along with volume-matched LY3841136-Placebo administered SC |
| Part B: LY3841136 + Tirzepatide-Placebo | EXPERIMENTAL | LY3841136 administered SC along with volume-matched Tirzepatide-Placebo administered SC |
| Part B: LY3841136 + Tirzepatide | EXPERIMENTAL | LY3841136 administered SC along with Tirzepatide administered SC |
| Part B: LY3841136-Placebo + Tirzepatide-Placebo | PLACEBO_COMPARATOR | Volume-matched LY3841136-Placebo administered SC along with volume-matched Tirzepatide-Placebo administered SC |
| LY3841136 (Part A) | EXPERIMENTAL | Single ascending doses of LY3841136 administered subcutaneously (SC). |
| LY3841136 (Part B) | EXPERIMENTAL | Multiple ascending doses of LY3841136 administered SC. |
| Placebo (Part A) | PLACEBO_COMPARATOR | Placebo administered SC. |
| Placebo (Part B) | PLACEBO_COMPARATOR | Placebo administered SC. |
| Name | Type | Description |
|---|---|---|
| LY3841136 | DRUG | Administered SC |
| Tirzepatide | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
| LY3841136-Placebo | DRUG | Administered SC |
| Tirzepatide-Placebo | DRUG | Administered SC |
Inclusion Criteria: W8M-MC-LAA2 * Have a Body Mass Index (BMI) of ≥27 kilograms per square meter (kg/m²) * Have Type 2 Diabetes * Have a HbA1c ≥7.0 % (53 millimoles/mole (mmol/mol)) to ≤10.5% (91 mmol/mol) and treated with diet and exercise alone or with a stable dose of metformin (and not more th...